MASCT by Hengrui Yuanzheng Biotechnology for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Kidney Cancer (Renal Cell Cancer).

Five Companies Sign Agreement to Participate in National Health Data-Sharing Network

WASHINGTON — Five healthcare companies took another step toward becoming part of a nationwide network to exchange patient health information on Tuesday. “I feel like

December 13, 2023

Gene therapy makers wonder if they can make a profit in Europe. Patients fear being left behind — again

LONDON — It was when she was 12 that doctors first raised the prospect of a medicine that could transform the disease Stella Pelteki had

October 4, 2023

People With ADHD Are Turning to AI Apps to Help With Tasks. Experts Express Caution.

Becky Litvintchouk didn’t think she’d be able to manage the mountain of tasks needed to become an entrepreneur. Every other part of her life has

August 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.